BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 18355852)

  • 1. PIK3CA, HRAS and KRAS gene mutations in human penile cancer.
    Andersson P; Kolaric A; Windahl T; Kirrander P; Söderkvist P; Karlsson MG
    J Urol; 2008 May; 179(5):2030-4. PubMed ID: 18355852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
    Hollestelle A; Elstrodt F; Nagel JH; Kallemeijn WW; Schutte M
    Mol Cancer Res; 2007 Feb; 5(2):195-201. PubMed ID: 17314276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mutational spectrum of HRAS, KRAS, NRAS and FGFR3 genes in bladder cancer.
    Ouerhani S; Elgaaied AB
    Cancer Biomark; 2011-2012; 10(6):259-66. PubMed ID: 22820081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenic mutations of the PIK3CA gene in head and neck squamous cell carcinomas.
    Murugan AK; Hong NT; Fukui Y; Munirajan AK; Tsuchida N
    Int J Oncol; 2008 Jan; 32(1):101-11. PubMed ID: 18097548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.
    Knobbe CB; Reifenberger J; Reifenberger G
    Acta Neuropathol; 2004 Dec; 108(6):467-70. PubMed ID: 15517309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.
    Janzarik WG; Kratz CP; Loges NT; Olbrich H; Klein C; Schäfer T; Scheurlen W; Roggendorf W; Weiller C; Niemeyer C; Korinthenberg R; Pfister S; Omran H
    Neuropediatrics; 2007 Apr; 38(2):61-3. PubMed ID: 17712732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low incidence of oncogenic EGFR, HRAS, and KRAS mutations in seborrheic keratosis.
    Georgieva IA; Mauerer A; Groesser L; Herschberger E; Aslanidis C; Dietmaier W; Landthaler M; Hafner C
    Am J Dermatopathol; 2014 Aug; 36(8):635-42. PubMed ID: 23739246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIK3CA gene mutations in pediatric and adult glioblastoma multiforme.
    Gallia GL; Rand V; Siu IM; Eberhart CG; James CD; Marie SK; Oba-Shinjo SM; Carlotti CG; Caballero OL; Simpson AJ; Brock MV; Massion PP; Carson BS; Riggins GJ
    Mol Cancer Res; 2006 Oct; 4(10):709-14. PubMed ID: 17050665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
    Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
    Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA mutations in glioblastoma multiforme.
    Hartmann C; Bartels G; Gehlhaar C; Holtkamp N; von Deimling A
    Acta Neuropathol; 2005 Jun; 109(6):639-42. PubMed ID: 15924253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
    Barbareschi M; Buttitta F; Felicioni L; Cotrupi S; Barassi F; Del Grammastro M; Ferro A; Dalla Palma P; Galligioni E; Marchetti A
    Clin Cancer Res; 2007 Oct; 13(20):6064-9. PubMed ID: 17947469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cis-acting genomic elements of the Pas1 locus control Kras mutability in lung tumors.
    Manenti G; Trincucci G; Pettinicchio A; Amendola E; Scarfò M; Dragani TA
    Oncogene; 2008 Sep; 27(43):5753-8. PubMed ID: 18560355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3, PIK3CA and RAS mutations in benign lichenoid keratosis.
    Groesser L; Herschberger E; Landthaler M; Hafner C
    Br J Dermatol; 2012 Apr; 166(4):784-8. PubMed ID: 22188534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma.
    Buttitta F; Felicioni L; Barassi F; Martella C; Paolizzi D; Fresu G; Salvatore S; Cuccurullo F; Mezzetti A; Campani D; Marchetti A
    J Pathol; 2006 Feb; 208(3):350-5. PubMed ID: 16353168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of somatic gene mutations in penile squamous cell carcinoma.
    Ferrándiz-Pulido C; Hernández-Losa J; Masferrer E; Vivancos A; Somoza R; Marés R; Valverde C; Salvador C; Placer J; Morote J; Pujol RM; Ramon y Cajal S; de Torres I; Toll A; García-Patos V
    Genes Chromosomes Cancer; 2015 Oct; 54(10):629-37. PubMed ID: 26216163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
    Kozaki K; Imoto I; Pimkhaokham A; Hasegawa S; Tsuda H; Omura K; Inazawa J
    Cancer Sci; 2006 Dec; 97(12):1351-8. PubMed ID: 17052259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA mutations in breast cancer are associated with poor outcome.
    Li SY; Rong M; Grieu F; Iacopetta B
    Breast Cancer Res Treat; 2006 Mar; 96(1):91-5. PubMed ID: 16317585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF, HRAS, KRAS, NRAS and CDKN2A genes analysis in cultured melanocytes used for vitiligo treatment.
    Czajkowski R
    Int J Dermatol; 2011 Feb; 50(2):180-3. PubMed ID: 21244382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of PIK3CA and Akt/protein kinase B in head and neck squamous cell carcinoma.
    Fenic I; Steger K; Gruber C; Arens C; Woenckhaus J
    Oncol Rep; 2007 Jul; 18(1):253-9. PubMed ID: 17549376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.